Up­dat­ed: GSK, iTeos re­ju­ve­nate strug­gling TIG­IT space with pos­i­tive Phase 2 Jem­per­li com­bo da­ta in lung can­cer

BARCELONA — GSK and iTeos have un­veiled pos­i­tive mid-stage da­ta for their PD-1 plus TIG­IT dou­blet in cer­tain lung can­cer pa­tients, bol­ster­ing ex­pec­ta­tions for an on­go­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER